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SUMMARY
In Iran, both Plasmodium vivax and P. falciparum malaria have been detected, but P. vivax is the predominant species. Point 
mutations in dihydrofolate reductase (dhfr) gene in both Plasmodia are the major mechanisms of pyrimethamine resistance. From 
April 2007 to June 2009, a total of 134 blood samples in two endemic areas of southern Iran were collected from patients infected with 
P. vivax and P. falciparum. The isolates were analyzed for P. vivax dihydrofolate reductase (pvdhfr) and P. falciparum dihydrofolate 
reductase (pfdhfr) point mutations using various PCR-based methods. The majority of the isolates (72.9%) had wild type amino acids 
at five codons of pvdhfr. Amongst mutant isolates, the most common pvdhfr alleles were double mutant in 58 and 117 amino acids 
(58R-117N). Triple mutation in 57, 58, and 117 amino acids (57L/58R/117N) was identified for the first time in the pvdhfr gene of 
Iranian P. vivax isolates. All the P. falciparum samples analyzed (n = 16) possessed a double mutant pfdhfr allele (59R/108N) and 
retained a wild-type mutation at position 51. This may be attributed to the fact that the falciparum malaria patients were treated using 
sulfadoxine–pyrimethamine (SP) in Iran. The presence of mutant haplotypes in P. vivax is worrying, but has not yet reached an alarming 
threshold regarding drugs such as SP. The results of this study reinforce the importance of performing a molecular surveillance by 
means of a continuous chemoresistance assessment.
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INTRODUCTION
Antifolates, most notably sulfadoxine–pyrimethamine (SP), are 
important in antimalarial therapy. They are inexpensive, relatively safe 
and treatment requires only a single dose1. The enzymes of SP, involved 
in the folate biosynthesis pathway of the parasite, are commonly used 
for Plasmodium falciparum malaria treatment2. Point mutations in the 
dihydrofolate reductase (dhfr) gene in both P. falciparum and P. vivax 
are the major mechanisms of pyrimethamine resistance3. The molecular 
mechanisms associated with two (2) key dhfr mutations, S58R and S117N, 
which are equivalent to the C59R and S108N mutations of the P. falciparum 
dihydrofolate reductase (pfdhfr) gene involved in the development of SP 
resistance in P. falciparum and P. vivax, are most likely similar. They are 
known to be associated with pyrimethamine resistance4. Substitution of 
serine to asparagine at codon 117, increased the IC50 value more than 80-
fold. The addition of a second mutation, resulting in the substitution of 
serine to arginine at codon 58, produced an enzyme that was more than 
400-fold resistant to pyrimethamine5. The distribution of mutant alleles 
of these genes in different geographical regions varied6. In Iran, national 
malaria control programs initiated in the 1950s led to the eradication 
of malaria in the northern Caspian region in 1977, and to a substantial 
reduction of transmission in the south-eastern provinces of Sistan and 
Baluchistan, Hormozgan and tropical regions of Kerman7-9. In this area, 
both P. vivax and P. falciparum malaria have been detected, but P. vivax 
is the predominant species that causes about 90-95% of the total malaria 
cases8,10. The standard treatment for this parasitic infection has been 
chloroquine (CQ) and primaquine for eradication of both asexual stages and 
hypnozoites11. A major challenge for the control and elimination of P. vivax 
is the emergence of drug-resistant strains. Chloroquine resistance (CQR) 
in P. vivax was first reported in 1989 from Papua New Guinea (PNG) and 
Indonesia in 199112,13. Since then, cases of resistance have been reported 
from several areas of the vivax endemic world 12-15. Chloroquine resistance 
has not been reported in Iran, but a declining trend of the parasite’s in vivo 
susceptibility to the drug has been noted10. This emphasizes the urgent 
need to search for alternative treatments for P. vivax infection, possibly 
including drugs of the antifolate class16. Although, SP has not been used 
for the treatment of P. vivax parasites in any vivax malaria endemic region 
so far, SP resistance in P. vivax has been reported17. These infections could 
be misdiagnosed or undiagnosed, and as a result, exposure of P. vivax to 
SP may lead to selection of SP-resistant strains.
A combination of CQ and primaquine had been used as a first line 
antimalarial drug for the treatment of uncomplicated P. falciparum in 
Iran up to 2005. Due to the prevalence of CQ-resistant parasites in this 
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region, SP plus CQ was officially introduced as the first line treatment 
for confirmed P. falciparum cases in 200618. Due to the inefficacy 
of treatment with the SP/CQ combination, the Center for Diseases 
Management and Control (CDMC) decided to revise the treatment 
policy in 2007, in which SP/CQ was replaced with SP/artesunate as 
the first-line recommendation for falciparum malaria19. However, 
SP resistance has been consistently reported among Afghan refugee 
settlements along the western border of Pakistan, a region from which 
human migration has recently increased substantially. This raises the 
concern that SP-resistant malaria parasites are now invading the nearby 
regions of Iran20. The widespread SP resistance in various endemic 
regions has been explained by the invasion and subsequent selection 
of resistant parasites in the presence of SP pressure21. Resistance to SP 
has been confirmed in malaria endemic areas of Iran by means of in 
vitro and in vivo tests22,23. A dhfr codon, Asn108 with Ile51 and Arg59, 
confers resistance to pyrimethamine and may predict SP treatment 
failure in some malaria endemic areas24. Moreover, understanding 
the epidemiology of drug resistance is necessary for an effective drug 
policy. In fact, routine monitoring makes it possible to detect drug 
resistance at early stages of development in order to avoid further 
selection and spread of multidrug resistance18. Therefore, in this study 
we report for the first time the frequencies of relevant mutations in 
pfdhfr and pvdhfr, among isolates obtained from two different endemic 
areas (Bandare Jask and Minab) of southern Iran.
MATERIALS AND METHODS
Site
In this study, a total of 134 blood samples were collected from 
P. vivax and P. falciparum malaria patients in two endemic areas of 
Hormozgan Province (Bandare Jask and Minab), located in the southern 
part of Iran, from April 2007 to June 2009. Hormozgan Province is 
one of the 31 provinces of Iran and is located in the northern coast of 
the Persian Gulf and the Gulf of Oman (Fig. 1); its area is 70,697 km² 
(27° 11’ 18.24” N, 56° 16’ 36.48” E), where the weather is warm and 
humid enough for Anopheles sp. to be active throughout the year. As 
such, this environmental condition makes An. stephensi the main vector 
responsible for the transmission of malaria to humans in southern Iran25. 
The average temperature affected by humidity is moderate and rarely gets 
higher than 45 °C in summers. The annual rainfall is less than 250 mm 
and the relative humidity is more than 80%26. In this area, malaria is 
seasonal and transmission is year-round with two peaks, the first from 
May to August with P. vivax as the predominant species and the second 
Fig. 1 - Map of Iran and Hormozgan province (http://geology.com/world/iran-satellite-image.shtml, http://www.operationworld.org/iran, http://www.irantravel.biz/iran_maps/hormozgan_
province.gif).
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peak from October to November when both P. falciparum and P. vivax 
infections were recorded27.
DNA extraction and PCR amplification
DNA was extracted using DNG-plus extraction Kit (Cinnagen, Iran), 
according to the manufacturer’s manual. The DNA pellet was dissolved 
in 50 µl of sterile distilled water, incubated in a water bath at 65 °C for 
5 min, and stored at -20 °C until use.
Two single PCR techniques were employed to amplify a partial DNA 
sequence containing some single nucleotide polymorphisms (SNPs) for 
target genes including: SNPs N51I, C59R, and S108N/T for pfdhfr and 
SNPs P33L, F57L/I, S58R, S117T/N and I173F/L for pvdhfr. 
Pvdhfr gene amplification: Oligonucleotide primers were used to 
amplify a fragment of 1,869 bp from pvdhfr gene using P. vivaxdhfr-ts 
gene (GenBank accession no. X98123). PCR, seminested-PCR and 
PCR-RFLP were performed as previously described28. 
Pfdhfr gene amplification: Oligonucleotide primers were used 
to amplify a fragment of 514 bp from pfdhfr gene using P. falciparum 
dhfr-ts gene (GenBank accession no. M22159). PCR was performed as 
previously described29.
PCR products were analyzed using ethidium bromide-stained 
agarose-gel (2%) electrophoresis.
Sequence analysis of pvdhfr and pfdhfr genes
To verify the results obtained by RFLP, and also search for new SNPs 
in pvdhfr gene, which covers the region that contains drug-resistance 
related point mutations, mutant isolates pvdhfr from five residues and 
some wild types isolates were confirmed by sequencing the PCR products 
in both directions using appropriate primers. Furthermore, pfdhfr gene 
polymorphisms of P. falciparum were evaluated by sequencing, and for 
this purpose, the PCR samples were treated with a pre-sequencing kit 
(USB Corporation, Cleveland, Ohio) then sequenced using an Applied 
Biosystems (ABI) terminator cycle sequencing ready reaction kit 
(BigDye1 Terminator V3.1 Cycle SequencingKit) on an ABI 3130 genetic 
analyzer. The sequences obtained were manually edited and aligned using 
the Gene Runner software (version 3.05). PCR and sequencing analysis 
of the isolates with mutations were repeated several times, to rule out 
any possible errors. 
Ethical approval
The study was approved by the Ethics Committee of the Infectious 
Diseases and Tropical Medicine Research Center, Shahid Beheshti 
University of Medical Sciences. All samples were collected with the 
consent of the patients or their relatives before the beginning of treatment, 
and stored at -20 °C until DNA extraction. P. vivax and P. falciparum 
were diagnosed using microscopic examination of the thin and thick 
blood smears, stained by Giemsa.
RESULTS
In this study, a sensitive PCR–RFLP and sequencing methods were 
used to analyze the frequency of mutations in defined residues of the 
Pvd hfr and pfdhfr gene related to pyrimethamine resistance in 79 (67%) 
males and 39 (33%) females, constituting 118 P. vivax, and 13 (81%) 
males and 3 (19%) females, constituting 16 P. falciparum isolates in 
the Hormozgan Province. Participants in this study were aged between 
4 to 70 years.
Distribution of mutations in pvdhfr: Forty six P. vivax isolates from 
Minab and 72 from Bandare Jask were analyzed for mutations at codons 
33, 57, 58, 117 and 173 of the P. vivax dhfr gene. Eighty-six of the isolates 
(72.9%) showed the wild type amino acids at the aforementioned five 
codons of pvdhfr (Table 1 and Fig. 2). Seventeen samples (37%) from 
Minab and 15 (20.8%) from Bandare Jask showed single, double or triple 
mutations (Table 1). Mutations at residues 173 (I→L) and 33 (P→L) were 
not detected in any of the analyzed samples and no mutation was seen in 
codon 57, in Bandare Jask isolates. Amongst mutant isolates, the most 
common pvdhfr alleles were double mutant (n: 25), with combination 
of two mutations, S58R-S117N or F57L-S58R and the remaining 7 
mutant isolates were single mutation for S117N (n: 4) or triple (n: 3) at 
F57L -S58R-S117N (Table 2). To verify the results obtained by RFLP, 
the 32 mutants and 12 wild type alleles were sequenced. Sequencing 
confirmed the RFLP results with no new point mutation in the wild or 
mutant samples.
Table 1
Plasmodium vivax dihydrofolate reductase (pvdhfr) variants classified according to the number of point mutations in two areas of Hormozgan province, Iran











Total 86 (72.9) 4 (3.4) 25 (21.2) 3 (2.5)
Fig. 2 - The frequency of mutant isolates in Plasmodium vivax dihydrofolate reductase (pvdhfr) 
gene of two areas of Hormozgan province, Iran.
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Size polymorphism of the pvdhfr at repeat region: A repetition 
(ACA CAC GGT GGT GAC AAC or ACA CAC GGT GGT GAC AAT) 
between amino acids 103 and 104 of pvdhfr was found in 3/44 and 2/44 
of the sequenced samples, respectively. Therefore, two types A and B 
were found among the isolates. The frequency distribution for types A 
and B were 88.7% (39/44) and 11.3% (5/44), respectively. Interestingly, 
all mutant alleles were type A (Table 3).
Distribution of mutations in Pfdhfr: All the 16 P. falciparum 
isolates were obtained from Bandare Jask and were successfully 
genotyped for detection of dhfr mutations associated with SP resistance. 
P. falciparum isolates were found to carry the mutant type 108N and 
59R (100%) while retaining a wild-type mutation at position 51 (Fig. 3).
All the allelic types of pvdhfr (7 types) and pfdhfr (1 type) were 
represented in the GenBank (accession number AB547452 –AB547459).
DISCUSSION
In areas where P. falciparum and P. vivax co-exist, parasite-specific 
diagnosis and choice of effective treatment is crucial to prevent the 
emergence and spread of resistance30. Mutation rate for pfdhfr was higher 
compared to pvdhfr because the drug was mainly given to treat falciparum 
malaria. The most common haplotypes of pvdhfr were the wild type 
and double mutants. Quadruple mutants were not detected in any of the 
examined isolates. The appearance of these SP resistant genotypes in P. 
vivax creates a need for new antimalarial drugs that should preferably 
be effective against both P. vivax and P. falciparum species31. After 
determining SP as the first line treatment of falciparum malaria in 2001 
in Iran4, it was expected that the trend of reducing sensitivity of P. vivax 
to the drug would be intensified, as reported in Thailand. Analyses of 
field isolates from Thailand, where SP has been extensively used in the 
past, revealed the predominance (100%) of parasites harboring 3 Pvdhfr 
mutant alleles; S58R and S117N; F57L, S58R, T61M and S117T; and 
F57I, S58R, T61M and S117T1,6. A majority of the isolates carrying 
mutations showed the presence of double mutations at residues 58R/117N 
(n. 20 or 17%) and 57L/58R (n. 5 or 4.2%), (Table 2). The prevalence 
and distribution of the resistant allelic types in Hormozgan Province 
are similar to those reported in China, East Timor, the Philippines, and 
Vietnam, where SP has not been widely used until recently1. A previous 
study27 in northern and south-eastern Iran reported similar frequencies 
of mutant alleles in codons 57, 58 and 117 with the exception of triple 
mutation in three samples (2.5%) of this study. The triple mutation in 
Table 2
Single, double and triple Plasmodium vivax dihydrofolate reductase (pvdhfr) nucleotide polymorphisms as point mutation for 57, 58, and 117 identified from two 
areas of Hormozgan province, Iran






29 (63)  














46 (100) 72 (100) 118 (100)
Table 3
Polymorphism in Plasmodium vivax dihydrofolate reductase (pvdhfr) gene related to two different types of tandem repeats
Group
Wild Mutant Total
No. % No. %
A 7 18 32 82 39 88.7
B 5 100 0 0 5 11.3
Total 12 27.3 32 72.7 44 100
A: KLKWKRERYLRMEASQGGGDNTSGGDNTHGGDNADKLQNVVVMG
B: KLKWKRERYLRMEASQGGGDNTSGGDNTHGGDNTHGGDNADKLQNVVVMG
Fig. 3 - Comparative of amino acids in mutant and wild type alleles in P. falciparum 
dihydrofolate reductase (pfdhfr) in P. falciparum isolates of Hormozgan province, Iran. Codon 
59 (Wild): → Cysteine (Cys or C); Codon 59 (Mutant): → Arginine (Arg or R); Codon 108 
(Wild): → Serine (Ser or S); Codon 108 (Mutant): → Asparagine (Asn or N); ShH(Pf)1J-IR 
(Accession No: AB547459).
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the 57L/58R/117N codons of this study is the first report of the pvdhfr 
gene, in Iranian P. vivax isolates. However, no quadruple mutant was 
identified. In another study in Iran, no mutation at codon 57 and no triple 
mutant alleles were seen. Furthermore, the mutant alleles of Hormozgan 
Province were rarely seen4 while 6.8% of the examined isolates were 
mutant at this codon and 27.1% of this study’s isolates were mutant. 
Mutations in pvdhfr, including 58R and 117N, have been implicated 
in in vivo pyrimethamine resistance and seem to arise first under drug 
pressure. Studies have shown that the 58R/117N mutant had a lower 
affinity for pyrimethamine and cycloguanil than the wild type enzyme32. 
SP has not been used for the treatment of P. vivax parasites in any vivax 
malaria endemic region of Iran. P. vivax and P. falciparum coexist in 
some areas, the correct diagnosis of mixed infections is not easy based on 
microscopic examination of blood smears and the clinical symptoms of 
the two species cannot be differentiated. As a result, P. vivax may often be 
treated with SP because of mixed infections and inaccurate diagnosis27,33. 
In addition, other antifolates such as co-trimoxazole that are routinely 
used against urinary tract infections and chronic bronchitis in the region 
could add to the overall antifolate pressure in Iran27. 
All the isolates in this study were mutant at codons 59 and 108 (100%) 
of pfdhfr and none of them was mutant at codon 51, with no evidence 
of clinical failure of SP in patients. Studies of genetic transfection 
of P. falciparum confirmed that the amino acid substitution at pfdhfr 
codon 108 (S→N) increases approximately ten times the resistance to 
pyrimethamine34, and the addition of mutations at codons 51, 59, and 
164 progressively increases the level of resistance2. In Iran, SP has not 
been widely used as monotherapy in first-line treatment. It was used as 
a combination therapy with CQ for only two years and then replaced by 
SP/artesunate. In fact, the high prevalence of mutations in dhfr might be 
affected by other chemically-related drugs such as co-trimoxazole, which 
is commonly used in the study areas for treating bacterial infections in 
the setting of malaria in Iran24. In addition, the high prevalence of these 
mutations in areas with low clinical failure to SP may be associated with 
prior primaquine exposure, which could explain the fixed prevalence of 
this mutation among isolates23. Furthermore, when SP was widely used, 
resistance developed relatively quickly. Therefore, the World Health 
Organization (WHO) recommends the use of combination therapies 
composed of two or more drugs that target different pathways in order 
to overcome resistance, in particular artemisinin combination therapies 
(ACTs)24. Although, the results of this study revealed the high prevalence 
of these two mutations in Iranian P. falciparum isolates, this has not 
yet reached a level at which SP will completely fail in the treatment of 
patients. Therefore, 51I mutation might be a good molecular marker for 
the triple mutant, indicating a failure of pyrimethamine in Iran.
CONCLUSION
This study determined the low molecular prevalence of resistance to 
SP in P. vivax and a high level of SP resistance in P. falciparum. In fact, 
the presence of mutant haplotypes in P. vivax is worrying, but has not 
yet reached an alarming threshold regarding drugs such as sulfadoxine–
pyrimethamine, unlike in many parts of the world. This indicates the 
emergence of drug tolerant/resistant P. vivax isolates in Iran in the near 
future. This study evaluated the implementation of new therapeutic 
strategies based on combinations that include SP, like the protocol that 
is now being implemented in Iran (artesunate combined with SP), as 
the first-line drug for uncomplicated malaria (P. falciparum) treatment.
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